Download PDF
neuroreha 2014; 06(01): 8-14
DOI: 10.1055/s-0034-1372451
Schwerpunkt Multiple Sklerose
Georg Thieme Verlag KG Stuttgart · New York

Multiple Sklerose im Überblick

Peter Flachenecker
1   Neurologisches Rehabilitationszentrum Quellenhof, Kuranlagenallee 2, 75323 Bad Wildbad
› Author Affiliations
Further Information

Publication History

Publication Date:
20 March 2014 (online)

    Permissions and Reprints

Zusammenfassung

Die Multiple Sklerose ist eine chronisch-entzündliche Erkrankung des zentralen Nervensystems. Trotz vielfältiger Forschungsaktivitäten sind die für den Ausbruch der Erkrankung verantwortlichen Faktoren immer noch weitgehend unbekannt. Allerdings haben die Forschungsbemühungen der letzten Jahre erheblich zum Verständnis der Erkrankung und deren Einflussfaktoren beigetragen und neue diagnostische Möglichkeiten eröffnet. Der Artikel bietet einen aktuellen Überblick zu verschiedenen Aspekten der MS: Epidemiologie und Genetik, klinisches Erscheinungsbild, diagnostische Möglichkeiten, Krankheitsverlauf und Prognose.

 

  • Literatur

  • 1 Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-135
    CrossrefGoogle Scholar
  • 2 Amato MP, Zipoli V, Goretti B et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006; 253: 1054-1059
    CrossrefGoogle Scholar
  • 3 Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504-513
    CrossrefGoogle Scholar
  • 4 Beecham AH, Patsopoulos NA, Xifara DK et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 10
    Google Scholar
  • 5 Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler 2009; 15: 891-898
    CrossrefGoogle Scholar
  • 6 Broadley SA. Could vitamin D be the answer to multiple sclerosis?. Mult Scler 2007; 13: 825-826
    CrossrefGoogle Scholar
  • 7 Bronnum-Hansen H, Stenager E, Hansen T et al. Survival and Mortality Rates among Danes with MS. Int MS J 2006; 13: 66-71
    Google Scholar
  • 8 Brück W, Stadelmann C. Pathologie und Pathophysiologie. In: Schmidt RM, Hoffmann F. Multiple Sklerose. Urban & Fischer; München: 2006: 33-42
    CrossrefGoogle Scholar
  • 9 Cristiano E, Rojas J, Romano M et al. The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review. Mult Scler 2013; 19: 844-854
    CrossrefGoogle Scholar
  • 10 Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817
    CrossrefGoogle Scholar
  • 11 Flachenecker P. MS aktuell. Klinik und Diagnostik. Band 1. ComMed Medizinischer Verlag; Schopfheim: 2010
    Google Scholar
  • 12 Flachenecker P, Hartung HP. Impfkomplikationen des ZNS. In: Hopf HC, Deuschl G, Diener HC, Reichmann H. Neurologie in Klinik und Praxis. Georg Thieme Verlag; Stuttgart: 1999: 893-896
    Google Scholar
  • 13 Flachenecker P, Kos D. Fatigue. In: Henze T. Recommendations on rehabilitation services for persons with multiple sclerosis in Europe. Rehabilitation in Multiple Sclerosis (RIMS); Brüssel: 2011: 18-19
    Google Scholar
  • 14 Flachenecker P, Rieckmann P. Sozioökonomische Aspekte der Multiplen Sklerose. Z Nervenheilk 2003; 22 (Suppl. 01) S39-S42
    Google Scholar
  • 15 Flachenecker P, Stuke K, Elias W et al. Multiple-Sklerose-Register in Deutschland. Ausweitung des Projektes 2005/2006 Dt Ärztebl; 2008. 105. 113-119
    Google Scholar
  • 16 Flachenecker P, Zettl UK. Epidemiologie. In: Schmidt RM, Hoffmann F. Multiple Sklerose. Urban & Fischer; München: 2012. a 11-17
    Google Scholar
  • 17 Flachenecker P, Zettl UK. Krankheitsverlauf und Prognose. In: Schmidt RM, Hoffmann F. Multiple Sklerose. Urban & Fischer; München: 2012. b 59-67
    Google Scholar
  • 18 Humm AM, Beer S, Kool J et al. Quantification of Uhthoff’s phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol 2004; 115: 2493-2501
    CrossrefGoogle Scholar
  • 19 Ip CW, Wiendl H. Neuromyelitis optica. Akt Neurol 2008; 35: 450-462
    Article in Thieme ConnectGoogle Scholar
  • 20 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
    CrossrefGoogle Scholar
  • 21 Leray E, Yaouanq J, Le PE et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913
    CrossrefGoogle Scholar
  • 22 Lucchinetti C, Brück W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717
    CrossrefPubMedGoogle Scholar
  • 23 Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-1104
    CrossrefPubMedGoogle Scholar
  • 24 Matiello M, Jacob A, Wingerchuk DM et al. Neuromyelitis optica. Curr Opin Neurol 2007; 20: 255-260
    CrossrefGoogle Scholar
  • 25 McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127
    CrossrefGoogle Scholar
  • 26 Menge T, Kieseier BC, Nessler S et al. Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol 2007; 20: 247-254
    CrossrefGoogle Scholar
  • 27 Multiple Sclerosis International Federation. Atlas of MS 2013. www.msif.org/includes/documents/cm_docs/2013/m/msif-atlas-of-ms-2013-report.pdf?=1 (Zugriff am 17.11.2013)
    Google Scholar
  • 28 Pittock SJ, Mayr WT, McClelland RL et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; a 62: 601-606
    CrossrefGoogle Scholar
  • 29 Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; b 62: 51-59
    CrossrefGoogle Scholar
  • 30 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
    CrossrefGoogle Scholar
  • 31 Ruprecht K. Multiple Sklerose und Epstein-Barr-Virus: Eine aktuelle Übersicht. Akt Neurol 2013; 40: 400-407
    Article in Thieme ConnectGoogle Scholar
  • 32 Sailer M, Fazekas F, Gass A et al. Zerebrale und spinale MRT-Untersuchung bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Röfo 2008; 180: 994-1001
    Google Scholar
  • 33 Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219
    CrossrefGoogle Scholar
  • 34 Schober S, König H, Meissner H et al. Kognitive Defizite bei Multipler Sklerose. DNP 2005; 12 (05) 28-33
    Google Scholar
  • 35 Stadelmann C, Albert M, Wegner C et al. Cortical pathology in multiple sclerosis. Curr Opin Neurol 2008; 21: 229-234
    CrossrefGoogle Scholar
  • 36 Stuke K, Flachenecker P, Zettl UK et al. Symptomatology of MS: results from the German MS Registry. J Neurol 2009; 256: 1932-1935
    CrossrefGoogle Scholar
  • 37 Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14: 314-324
    CrossrefGoogle Scholar
  • 38 Tremlett H, Yousefi M, Devonshire V et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73: 1616-1623
    CrossrefGoogle Scholar
  • 39 Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007; 20: 269-274
    CrossrefGoogle Scholar